Mesenchymal stem cells(HucMSCs): B2278 is mesenchymal stem cells derived from human umbilical cord.
CABG: only CABG
Study summary
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated.
This trial is a multi-center I/II phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* 1\) Age from 18 to 80 years, both genders are eligible ;
* 2\) Clinically judged to be suitable for CABG treatment due to chronic ischemic cardiomyopathy;
* 3\) LVEF (left ventricular ejection fraction) is ≤ 40% as indicated by echocardiography (modified Simpson method) or cardiac magnetic resonance (CMR);
* 4\) NYHA (New York Heart Association) cardiac function classification of grade II-IV;
* 5\) Patients or their legal guardians agreed to participate in this trial and signed the informed consent form.
Major exclusion Criteria:
* 1\) Severe left ventricular dysfunction, with LVEF ≤ 20% (based on the UCG or CMR examination results during the screening period);
* 2\) Non-ischemic chronic left heart dysfunction, including but not limited to acute left heart dysfunction, dilated cardiomyopathy, severe right heart dysfunction (such as bilateral lower extremity edema accompanied by jugular vein distension, liver enlargement, etc.) or severe pulmonary hypertension (PASP \> 70 mmHg);
* 3\) Clinically determined that other surgical procedures need to be performed simultaneously during CABG surgery, including but not limited to congenital heart disease requiring concurrent surgical intervention, heart valve disease, ventricular aneurysm, ventricular septal perforation, papillary muscle dysfunction, aortic dissection, intracardiac mass, thrombus or neoplasm；
* 4\) Acute ST-segment elevation myocardial infarction or stroke event within 1 month before enrollment；
* 5\) Uncontrolled malignant arrhythmia;
* 6)have undergone or are awaiting heart transplantation or implantation of a left ventricular assist device (LVAD).
Primary outcome measure(s)
In phase I, primary outcome will be measured with safety events including DLT, AE, SAE, TEAE, and MACE. In phase II, primary outcome will be measured with the change in LVEF based on CMR detection after 6 months of administration. — 6 months
Trial sites (4)
Facility
City
Region
Status
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai
Shanghai Municipality
Recruiting
Changhai Hospital
Shanghai
Shanghai Municipality
Not Yet Recruiting
Shanghai Chest Hospital
Shanghai
Shanghai Municipality
Not Yet Recruiting
Shanghai General Hospital
Shanghai
Shanghai Municipality
Recruiting
More Tasly Pharmaceutical Group Co., Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.